Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc., a clinical-stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing cell-based technologies, including immune cell therapy for treating a range of cancer indications, comprising technologies in chimeric antigen receptor-modified T cells (CAR-T), T-cells with genetically modified tumor antigen-specific T-cell receptors, next-generation neoantigen-reactive biomarkers-based tumor infiltrating lymphocytes, and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha-fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor-infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in the biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. Cellular Biomedicine Group, Inc. was incorporated in 2013 and is based in Rockville, Maryland with additional locations in Admiralty, Hong Kong and Shanghai and Jiangsu, China.